AR044935A1 - Multiparticulados que contienen oxicodona - Google Patents

Multiparticulados que contienen oxicodona

Info

Publication number
AR044935A1
AR044935A1 ARP040102264A ARP040102264A AR044935A1 AR 044935 A1 AR044935 A1 AR 044935A1 AR P040102264 A ARP040102264 A AR P040102264A AR P040102264 A ARP040102264 A AR P040102264A AR 044935 A1 AR044935 A1 AR 044935A1
Authority
AR
Argentina
Prior art keywords
oxycodone
containing oxycodone
multiparticulates containing
multiparticulates
water
Prior art date
Application number
ARP040102264A
Other languages
English (en)
Spanish (es)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0315137A external-priority patent/GB0315137D0/en
Priority claimed from GB0403102A external-priority patent/GB0403102D0/en
Priority claimed from GB0413454A external-priority patent/GB0413454D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR044935A1 publication Critical patent/AR044935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040102264A 2003-06-27 2004-06-25 Multiparticulados que contienen oxicodona AR044935A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0315137A GB0315137D0 (en) 2003-06-27 2003-06-27 Multiparticulates
GB0403102A GB0403102D0 (en) 2004-02-12 2004-02-12 Multiparticulates
GB0413454A GB0413454D0 (en) 2004-06-16 2004-06-16 Multiparticulates

Publications (1)

Publication Number Publication Date
AR044935A1 true AR044935A1 (es) 2005-10-12

Family

ID=33556051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102264A AR044935A1 (es) 2003-06-27 2004-06-25 Multiparticulados que contienen oxicodona

Country Status (25)

Country Link
EP (2) EP1889621B1 (fr)
JP (2) JP5348841B2 (fr)
KR (1) KR101116518B1 (fr)
AR (1) AR044935A1 (fr)
AT (1) ATE453394T1 (fr)
AU (1) AU2004251481B2 (fr)
BR (1) BRPI0411901B1 (fr)
CA (1) CA2530385C (fr)
CY (2) CY1109917T1 (fr)
DE (1) DE602004024888D1 (fr)
DK (2) DK1644002T3 (fr)
EA (1) EA013424B1 (fr)
ES (2) ES2490598T3 (fr)
HR (2) HRP20100127T1 (fr)
IL (1) IL172730A (fr)
MX (1) MXPA05013799A (fr)
MY (1) MY176831A (fr)
NO (1) NO20060443L (fr)
NZ (1) NZ544181A (fr)
PE (1) PE20050286A1 (fr)
PL (2) PL1889621T3 (fr)
PT (2) PT1644002E (fr)
SI (2) SI1644002T1 (fr)
TW (1) TWI357815B (fr)
WO (1) WO2005000310A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1429739A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
KR20090029856A (ko) * 2005-01-28 2009-03-23 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2144599B1 (fr) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Granules à libération prolongée utilisant des matières cireuses
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
JP4879351B2 (ja) 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
EP2344136B1 (fr) * 2008-09-18 2016-06-15 Purdue Pharma LP Formes galeniques comprenant de la poly(e-caprolactone)
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
WO2010103039A1 (fr) 2009-03-10 2010-09-16 Euro-Celtique S.A. Compositions pharmaceutiques à libération immédiate comportant de l'oxycodone et du naloxone
EP2445487A2 (fr) 2009-06-24 2012-05-02 Egalet Ltd. Formulations à libération contrôlée
AU2010345740A1 (en) * 2010-02-11 2012-09-20 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
WO1992002211A1 (fr) * 1990-08-09 1992-02-20 Endocon, Inc. Systeme d'administration de medicaments multiples
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
WO1995022319A1 (fr) * 1994-02-16 1995-08-24 Abbott Laboratories Mode de preparation de formulations pharmaceutiques a fines particules
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CA2219995C (fr) * 1995-05-01 2004-04-13 Sam Yang Co., Ltd. Membrane bioresorbable implantable et son procede de preparation
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
WO1997045091A2 (fr) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Formulations d'oxycodone a liberation prolongee sans effet sur l'etat alimente/a jeun
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
ATE526950T1 (de) * 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2517710B1 (fr) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Formules agonistes opioïdes orales inviolables
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
CA2484632C (fr) * 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Procedes de fabrication d'un distributeur de medicaments
EP1592411A2 (fr) * 2003-01-24 2005-11-09 Control Delivery Systems, Inc. Liberation controlee d'agents hautement solubles
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates

Also Published As

Publication number Publication date
EA013424B1 (ru) 2010-04-30
CA2530385A1 (fr) 2005-01-06
TW200510000A (en) 2005-03-16
HRP20140635T1 (hr) 2014-09-26
MXPA05013799A (es) 2006-03-13
ES2337468T3 (es) 2010-04-26
JP2007520429A (ja) 2007-07-26
IL172730A0 (en) 2006-04-10
IL172730A (en) 2010-12-30
PL1644002T3 (pl) 2010-05-31
DE602004024888D1 (de) 2010-02-11
JP5960089B2 (ja) 2016-08-02
PE20050286A1 (es) 2005-06-13
SI1889621T1 (sl) 2014-09-30
BRPI0411901A (pt) 2006-08-08
ATE453394T1 (de) 2010-01-15
ES2490598T3 (es) 2014-09-04
CY1109917T1 (el) 2014-09-10
NZ544181A (en) 2008-12-24
JP5348841B2 (ja) 2013-11-20
PL1889621T3 (pl) 2014-10-31
CA2530385C (fr) 2013-05-28
AU2004251481A1 (en) 2005-01-06
DK1644002T3 (da) 2010-04-19
KR20060026892A (ko) 2006-03-24
KR101116518B1 (ko) 2012-03-13
EP1644002A1 (fr) 2006-04-12
SI1644002T1 (sl) 2010-03-31
HRP20100127T1 (hr) 2010-04-30
JP2013209387A (ja) 2013-10-10
CY1115415T1 (el) 2017-01-04
WO2005000310A1 (fr) 2005-01-06
EP1644002B1 (fr) 2009-12-30
EA200600111A1 (ru) 2006-06-30
EP1889621A1 (fr) 2008-02-20
NO20060443L (no) 2006-01-27
EP1889621B1 (fr) 2014-05-21
DK1889621T3 (da) 2014-08-11
AU2004251481B2 (en) 2010-01-28
BRPI0411901B1 (pt) 2019-04-02
PT1644002E (pt) 2010-03-03
NO333779B1 (fr) 2013-09-16
TWI357815B (en) 2012-02-11
PT1889621E (pt) 2014-08-27
MY176831A (en) 2020-08-24

Similar Documents

Publication Publication Date Title
AR044935A1 (es) Multiparticulados que contienen oxicodona
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
UY31497A1 (es) Nuevos compuestos para el tratamiento de trastornos del snc
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
AR109263A2 (es) Composición que comprende moxidectina
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR050616A1 (es) Composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos.
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY28312A1 (es) Pirazolopirimidinas sustituidas con 6-ciclimetilo y 6-alquilmetilo
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
AR031761A1 (es) Kit de repinotano
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
EA201490881A1 (ru) Органогель, структурированный 12-hsa и выбранным сополимером
AR043173A1 (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular
DK1220676T3 (da) Forebyggelse af colorektal cancer
DK1537132T3 (da) Salt af mortin-6-glucuronid
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
UY28390A1 (es) Multiparticulados
AR031404A1 (es) Una composicion y metodo de aplicacion
PA8644501A1 (es) Composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal